Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Avenciguat Clear all
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 1, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 1, 2026, 11:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

NCT06272058
View directory record Official record
Conditions
Healthy, Liver Diseases
Interventions
Avenciguat (BI 685509)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 1, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

NCT04736628
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Avenciguat, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Canyon Country, California • Rancho Cucamonga, California • Victorville, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 1, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481
View directory record Official record
Conditions
Hypertension, Portal
Interventions
Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 1, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

NCT04750577
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Placebo matching BI 685509, BI 685509
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Victorville, California • Waterbury, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 1, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT05559580
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Avenciguat (BI 685509), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 1, 2026, 11:24 PM EDT